Ribavirin ameliorates experimental autoimmune encephalomyelitis in rats and modulates cytokine production.

[1]  Inna N. Lavrik,et al.  Life and death in peripheral T cells , 2007, Nature Reviews Immunology.

[2]  D. Sacks,et al.  CD4+CD25−Foxp3− Th1 cells are the source of IL-10–mediated immune suppression in chronic cutaneous leishmaniasis , 2007, The Journal of experimental medicine.

[3]  Richard A. Flavell,et al.  Conventional T-bet+Foxp3− Th1 cells are the major source of host-protective regulatory IL-10 during intracellular protozoan infection , 2007, The Journal of experimental medicine.

[4]  M. Filippi,et al.  Glatiramer acetate therapy for multiple sclerosis: a review , 2006, Expert opinion on drug metabolism & toxicology.

[5]  R. J. Hocking,et al.  Signals mediated by transforming growth factor-β initiate autoimmune encephalomyelitis, but chronic inflammation is needed to sustain disease , 2006, Nature Immunology.

[6]  K. Murphy,et al.  Th17: an effector CD4 T cell lineage with regulatory T cell ties. , 2006, Immunity.

[7]  B. Engelhardt.  Molecular mechanisms involved in T cell migration across the blood–brain barrier , 2006, Journal of Neural Transmission.

[8]  Wolfgang Brück,et al.  The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage , 2005, Journal of Neurology.

[9]  T. Ziemssen,et al.  The role of the humoral immune system in multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE). , 2005, Autoimmunity reviews.

[10]  F. Lublin.  History of modern multiple sclerosis therapy , 2005, Journal of Neurology.

[11]  S. Khoury,et al.  Cytokines in multiple sclerosis: from bench to bedside. , 2005, Pharmacology & therapeutics.

[12]  T. Owens,et al.  The changing face of cytokines in the brain: perspectives from EAE. , 2005, Current pharmaceutical design.

[13]  C. Musselli,et al.  Antigenized antibodies expressing Vβ8.2 TCR peptides immunize against rat experimental allergic encephalomyelitis , 2004, Journal of immune based therapies and vaccines.

[14]  D. Green,et al.  Activation‐induced cell death in T cells , 2003, Immunological reviews.

[15]  L. Rakić,et al.  Ribavirin reduces clinical signs and pathological changes of experimental autoimmune encephalomyelitis in Dark Agouti rats , 2003, Journal of neuroscience research.

[16]  M. Mostarica‐Stojković,et al.  Down-regulation of experimental allergic encephalomyelitis in DA rats by tiazofurin , 2002, Journal of Neuroimmunology.

[17]  S. Hulshof,et al.  Cellular localization and expression patterns of interleukin‐10, interleukin‐4, and their receptors in multiple sclerosis lesions , 2002, Glia.

[18]  G. Trinchieri.  Regulatory Role of T Cells Producing both Interferon γ and Interleukin 10 in Persistent Infection , 2001, The Journal of experimental medicine.

[19]  Z. Hong,et al.  Mechanisms of Action of Ribavirin in Antiviral Therapies , 2001, Antiviral chemistry & chemotherapy.

[20]  S. Hodgkinson,et al.  Mycophenolate mofetil treatment accelerates recovery from experimental allergic encephalomyelitis. , 2001, International immunopharmacology.

[21]  H. Lassmann,et al.  Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis. , 2001, Immunity.

[22]  M. Shiffman,et al.  Alpha interferon combined with ribavirin potentiates proliferative suppression but not cytokine production in mitogenically stimulated human lymphocytes. , 2000, Antiviral research.

[23]  D. Braguer,et al.  Ribavirin-induced resistance to heat shock, inhibition of the Ras-Raf-1 pathway and arrest in G(1). , 2000, European journal of pharmacology.

[24]  Y. Matsumoto,et al.  Characterization of acute versus chronic relapsing autoimmune encephalomyelitis in DA rats , 2000, Journal of Neuroimmunology.

[25]  A. Allison,et al.  Mycophenolate mofetil and its mechanisms of action. , 2000, Immunopharmacology.

[26]  P. Franchetti,et al.  Nucleoside and non-nucleoside IMP dehydrogenase inhibitors as antitumor and antiviral agents. , 1999, Current medicinal chemistry.

[27]  U. Phan,et al.  Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. , 1999, Journal of hepatology.

[28]  Ming Liu,et al.  Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. , 1998, Journal of immunology.

[29]  T. Olsson,et al.  Cytokines in relapsing experimental autoimmune encephalomyelitis in DA rats: persistent mRNA expression of proinflammatory cytokines and absent expression of interleukin-10 and transforming growth factor-β , 1996, Journal of Neuroimmunology.

[30]  J. Merrill,et al.  Cytokines in inflammatory brain lesions: helpful and harmful , 1996, Trends in Neurosciences.

[31]  M. Herzum,et al.  Immunosuppressive treatment for myocarditis and dilated cardiomyopathy. , 1995, European heart journal.

[32]  M. Seidman,et al.  IL‐3 and ribavirin induce differentiation and growth suppression during long‐term treatment of a megakaryocytic leukemia cell line , 1995, Journal of cellular physiology.

[33]  M. Pender,et al.  Autoimmune neurological disease: Autoimmune diseases of the neuromuscular junction and other disorders of the motor unit , 1995 .

[34]  T. Olsson,et al.  Cytokine production in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis: dynamics of mRNA expression for interleukin-10, interleukin-12, cytolysin, tumor necrosis factor α and tumor necrosis factor β , 1995, Journal of Neuroimmunology.

[35]  C. Raine,et al.  The adhesion molecule and cytokine profile of multiple sclerosis lesions , 1995, Annals of neurology.

[36]  A. Allison,et al.  Preferential suppression of lymphocyte proliferation by mycophenolic acid and predicted long-term effects of mycophenolate mofetil in transplantation. , 1994, Transplantation proceedings.

[37]  Y. Natsumeda,et al.  Characterization of human type I and type II IMP dehydrogenases. , 1993, The Journal of biological chemistry.

[38]  M. Boudreaux,et al.  Toxicologic effects of ribavirin in cats , 1993, Journal of veterinary pharmacology and therapeutics.

[39]  H. Weiner,et al.  Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain , 1992, The Journal of experimental medicine.

[40]  M. Sporn,et al.  Evidence of endogenous regulatory function of transforming growth factor-beta 1 in experimental allergic encephalomyelitis. , 1992, International immunology.

[41]  D. Constam,et al.  Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia. , 1992, Journal of immunology.

[42]  C. Crumpacker,et al.  Inhibition of immune functions by antiviral drugs. , 1991, The Journal of clinical investigation.

[43]  W. B. Jolley,et al.  Long-term skin allograft survival by combined therapy with suboptimal dose of cyclosporine and ribavirin. , 1988, Transplantation proceedings.

[44]  V. Knight,et al.  Biochemistry and clinical applications of ribavirin , 1986, Antimicrobial Agents and Chemotherapy.

[45]  W. Sadee,et al.  Biochemical differences among four inosinate dehydrogenase inhibitors, mycophenolic acid, ribavirin, tiazofurin, and selenazofurin, studied in mouse lymphoma cell culture. , 1985, Cancer research.

[46]  W. Koff,et al.  Inhibition of lymphocyte proliferative responses by ribavirin , 1980, Infection and immunity.

[47]  L. Klassen,et al.  Ribavirin treatment in murine autoimmune disease. I. Therapeutic efficacy and effect on the immune response. , 1979, Arthritis and rheumatism.

[48]  L. Klassen,et al.  Ribavirin: efficacy in the treatment of murine autoimmune disease. , 1977, Science.

[49]  J. R. Kanwar.  Anti-inflammatory immunotherapy for multiple sclerosis/experimental autoimmune encephalomyelitis (EAE) disease. , 2005, Current medicinal chemistry.

[50]  S. Miller,et al.  Regulation of experimental autoimmune encephalomyelitis (EAE) by CD4+CD25+ regulatory T cells. , 2003, Novartis Foundation symposium.

[51]  S. Khoury,et al.  Cytokine shifts and tolerance in experimental autoimmune encephalomyelitis , 2003, Immunologic research.

[52]  B. Weinshenker,et al.  Multiple sclerosis. , 2000, The New England journal of medicine.

[53]  G. Weber,et al.  Ribavirin and quercetin synergistically downregulate signal transduction and are cytotoxic in human ovarian carcinoma cells. , 1999, Oncology research.

[54]  H. Weiner,et al.  IL-4-Deficient and Transgenic Mice Demonstrated by Studies of IL-10- and Autoimmune Encephalomyelitis as IL-10 Is Critical in the Regulation of , 1998 .

[55]  M. Pender.  Experimental Autoimmune Encephalomyelitis , 1995 .

[56]  L. Steinman,et al.  The T lymphocyte in experimental allergic encephalomyelitis. , 1990, Annual review of immunology.

[57]  W. Kirkpatrick,et al.  Ribavirin, a broad spectrum antiviral agent , 1980 .